HDFC Bank Limited has announced the re-appointment of Sunita Maheshwari as an Independent Director for a fresh three-year term, extending from March 30, 2026 to March 29, 2029 (both days inclusive). The decision, taken by the bank’s Board at its meeting today on the recommendation of the Governance, Nomination & Remuneration Committee, awaits shareholders’ approval before taking effect. The move underscores the bank’s commitment to strengthening its board with experienced, independent oversight as it navigates a rapidly evolving financial and digital landscape.
Sunita Maheshwari brings more than three decades of cross-border leadership in medicine and technology to the table. A US Board-certified pediatric cardiologist, she has built a track record as a medical entrepreneur and co-founder of the Telerad Group, which includes A-Kal Televerse and Telerad Tech. Her work spans telehealth platforms, AI-enabled software, and a network of telemedicine and neighborhood clinics, reflecting a rare blend of clinical insight and technology entrepreneurship that informs a broad view of governance and risk in today’s digital age.
In addition to her corporate and clinical laurels, Maheshwari has played active roles in education and social impact initiatives, including leadership of industry bodies and involvement in philanthropic ventures. The bank notes that she is not related to any other director or KMP and is not debarred from holding the office of a director by any SEBI or other authority, reinforcing the emphasis on independent oversight. The re-appointment will be presented to HDFC Bank’s shareholders for approval, following the board meeting that began at 1:30 p.m. and concluded at 4:00 p.m.
As HDFC Bank continues to fuse financial services with technology-enabled solutions, Sunita Maheshwari’s diverse background in healthcare innovation and digital health governance offers a distinctive perspective for a board charged with guiding strategy, risk, and long-term value creation. Her profile, captured in Annexure-I of the filing, paints a portrait of a leader who has built bridges between clinical excellence and scalable technology ventures, potentially informing governance choices at the bank in moments of disruption and opportunity.